AdAlta (1AD) Stock Overview
A clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
1AD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
AdAlta Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.004 |
| 52 Week High | AU$0.008 |
| 52 Week Low | AU$0.002 |
| Beta | 0.031 |
| 1 Month Change | 0% |
| 3 Month Change | -33.33% |
| 1 Year Change | -33.32% |
| 3 Year Change | -84.61% |
| 5 Year Change | -97.42% |
| Change since IPO | -98.57% |
Recent News & Updates
Recent updates
Is AdAlta (ASX:1AD) A Risky Investment?
Oct 11
Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For Now
Nov 16Is AdAlta (ASX:1AD) Using Debt Sensibly?
Sep 02We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate
Jun 11Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth
Feb 26Shareholder Returns
| 1AD | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | 0.3% |
| 1Y | -33.3% | -39.9% | 14.9% |
Return vs Industry: 1AD exceeded the Australian Biotechs industry which returned -39.9% over the past year.
Return vs Market: 1AD underperformed the Australian Market which returned 14.9% over the past year.
Price Volatility
| 1AD volatility | |
|---|---|
| 1AD Average Weekly Movement | 24.9% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 10.5% |
| 10% most volatile stocks in AU Market | 17.8% |
| 10% least volatile stocks in AU Market | 4.5% |
Stable Share Price: 1AD's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: 1AD's weekly volatility has decreased from 32% to 25% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 1 | Tim Oldham | www.adalta.com.au |
AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. It has discovered WD-34 for the multiple malaria species, Babesia, and Toxoplasma in collaboration with La Trobe University.
AdAlta Limited Fundamentals Summary
| 1AD fundamental statistics | |
|---|---|
| Market cap | AU$10.20m |
| Earnings (TTM) | -AU$4.36m |
| Revenue (TTM) | AU$608.07k |
Is 1AD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1AD income statement (TTM) | |
|---|---|
| Revenue | AU$608.07k |
| Cost of Revenue | AU$219.37k |
| Gross Profit | AU$388.71k |
| Other Expenses | AU$4.75m |
| Earnings | -AU$4.36m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0017 |
| Gross Margin | 63.92% |
| Net Profit Margin | -717.51% |
| Debt/Equity Ratio | 0% |
How did 1AD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/16 18:53 |
| End of Day Share Price | 2026/04/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AdAlta Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maxim Jacobs | Edison Investment Research |
| Scott Power | Morgans Financial Limited |
| Derek Jellinek | Morgans Financial Limited |